Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2020 08:00 ET | Source: Foamix, Ltd.

Foamix Pharmaceuticals to Present at the Cowen and Company’s 40th Annual Health Care Conference

REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on...
February 18, 2020 08:00 ET | Source: Foamix, Ltd.

Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea

REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on...
February 06, 2020 13:00 ET | Source: Foamix, Ltd.

Foamix and Menlo Announce Shareholder Approval of Proposed Merger

REHOVOT, Israel and BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today...
February 06, 2020 08:00 ET | Source: Foamix, Ltd.

Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology

REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company,...
January 17, 2020 08:00 ET | Source: Foamix, Ltd.

Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics

REHOVOT, Israel, and BRIDGEWATER, N.J., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today...
January 14, 2020 08:00 ET | Source: Foamix, Ltd.

Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.

Preferred Coverage Effective Immediately on Express Scripts National Preferred, Flex, and Basic Formularies AMZEEQ is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate...
January 09, 2020 08:00 ET | Source: Foamix, Ltd.

Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne

AMZEEQ is the First FDA Approved Topical Form of Minocycline and the Company’s First Commercial Launch AMZEEQ Offers Efficacy with Low Systemic Absorption List price of $485...
November 25, 2019 08:00 ET | Source: Foamix, Ltd.

Foamix Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference

REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today...
November 18, 2019 08:00 ET | Source: Foamix, Ltd.

Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, today announced the...
November 11, 2019 06:00 ET | Source: Foamix, Ltd.

Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update

REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on...

Next Page keyboard_arrow_right